Aethlon Medical Amends ATM Program, Authorizing Sale of Up To $542K More Stock
AEMD sits 51% above its 52-week low of $1.36.
Summary
Aethlon Medical has amended its At-The-Market (ATM) offering agreement, enabling it to sell up to an additional $542,716 of common stock, following previous sales of $1.85 million under the same program.
Key Events · Financing and Capital Events · AEMD
-
ATM Program Amendment
Aethlon Medical filed an amendment to its At-The-Market (ATM) offering agreement, originally established in March 2022 and amended in December 2025.
-
Increased Capital Raise Capacity
The amendment authorizes the company to offer and sell up to an additional $542,716 in common stock through the ATM program.
-
Prior Sales Under Program
The company has already sold $1,849,457 worth of common stock under this ATM program prior to this amendment.
-
Going Concern Context
This ongoing capital raise is crucial for the company, which previously issued a going concern warning due to insufficient cash for the next 12 months.
Analysis · AEMD · Industrial Applications And Services
This filing updates the company's At-The-Market (ATM) offering program, allowing it to sell an additional $542,716 in common stock. This capital raise is critical for Aethlon Medical, which previously disclosed a going concern warning and insufficient cash for the next 12 months. While dilutive for existing shareholders, the ability to continue raising funds is essential for the company's operational runway.
At the time of this filing, AEMD was trading at $2.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $1.36 to $29.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.